Studies have also reported that cooperation between somatic mutations such as FLT3 and TET2 or NPM1 leads to an increase in epigenetic diversity in AML cells, and an enhanced epigenetic diversity has been associated with inferior patient outcomes [72,76,79]. This evidence concerns the gene TET2 and acute myeloid leukemia.